CA
NZ
UK
AU
IND
US
CYBIN INC. (NASDAQ: HELP) reported Eric So’s 5.8% beneficial ownership, including 105,264 common shares underlying warrants. So purchased 95,000 common shares on September 1, 2026, for $1,121,475. CYBIN INC. Also awarded him 1,046,899 restricted stock units.
Denali Therapeutics Inc. (NASDAQ: DNLI) Chief Medical Officer Chin Peter Scott sold 1,654 shares at $22.29 per share. The transaction occurred on 4 September 2026.
Editas Medicine, Inc. (NASDAQ: EDIT) awarded 950,000 derivative securities to Ory Daniel Scott, its executive vice president and chief medical officer. The transaction was recorded on 8 September 2026. Scott’s resulting derivative-securities holding was also 950,000.
Elanco Animal Health Inc (NYSE: ELAN) awarded derivative securities to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen at $24.50 per share. The transaction represented about 5.4% of his resulting derivative-securities holding. The recipient is identified as an executive officer of Elanco …
Century Therapeutics, Inc. (NASDAQ: IPSC) has expanded its board with Joseph Truitt, granting him an initial option to purchase 148,000 common shares. Truitt’s appointment took effect on September 9, 2026, and he will also receive a $40,000 annual cash retainer as a non-employee director.
Century Therapeutics, Inc. (NASDAQ: IPSC) CEO Brent Pfeiffenberger forfeited 463 shares at $2.11 per share, leaving him with 3,633,839 shares. The transaction represented about 0.0% of his prior holding.
Carr Douglas, SVP Finance & Operations at Century Therapeutics, Inc. (NASDAQ: IPSC), sold 254 shares at $2.05 per share. The transaction occurred on 8 September 2026 and left Douglas holding 504,565 Century Therapeutics shares.
Ascendis Pharma A/S (NASDAQ: ASND) said once-weekly TransCon CNP produced a mean +3.15 mm change from baseline in the sagittal diameter of the foramen magnum in infants with achondroplasia. The Week 52 data also showed stabilization or improvement in cranio-cervical junction health alongside linear …
Protocol Adds Post-Treatment Weight-Regain Assessment
BIO-RAD LABORATORIES, INC. (NYSE: BIO) executive Eva Anette Engelhardt exercised options covering 2,179 shares at $0 per share across separate transactions. The reported records also show her ownership at 2,313 shares following those transactions.
Please wait processing your request...